St. John's wort: Role of active compounds for its mechanism of action and efficacy

Wiener Medizinische Wochenschrift

Volumn 157, Issue 13-14, 2007, Pages 356-361

  Butterweck, Veronika ^a   Schmidt, Mathias ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Herbresearch ^*  (Germany)

Author keywords

Active constituents; Clinical efficacy; Hypericum perforatum; Pharmacology

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; FLAVONOID; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; NAPHTHODIANTHRONE DERIVATIVE; NEUROTRANSMITTER; PSEUDOHYPERICIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; NONHUMAN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; CELLS, CULTURED; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERICUM; ICE; META-ANALYSIS; PERYLENE; PHLOROGLUCINOL; PHYTOTHERAPY; PLANT EXTRACTS; TERPENES;

EID: 34548442151     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-007-0440-8     Document Type: Article

References (61)

1. Linde K, Mulrow CD, Egger M (2005) St. John's Wort for depression. Cochrane Database Syst Rev: CD000448
2. Clement K, Covertson CR, Johnson MJ, Dearing K (2006) St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 20: 197-203
3. Butterweck V (2003) Mechanism of action of St John's wort in depression: what is known? CNS Drugs 17: 539-562
4. Greeson JM, Sanford B, Monti DA (2001) St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 153: 402-414
5. Mennini T, Gobbi M (2004) The antidepressant mechanism of Hypericum perforatum. Life Sci 75: 1021-1027
6. Nathan PJ (2001) Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 15: 47-54
7. Sparenberg B, Demisch L, Hölzl J (1993) Untersuchungen über antidepressive Wirkstoffe von Johanniskraut. Pharm Z Wiss 138: 50-54
8. Berghöfer R, Hölzl J (1986) Johanniskraut (Hypericum perforatum L.) - Prüfung auf Verfälschung. Dtsch Apoth Ztg 47: 2569-2573
9. Cellarova E, Daxnerova Z, Kimakova K, Haluskova J (1994) The variability of the hypericin content in the regenerants of Hypericum perforatum. Acta Biotechnologica 14: 267-274
10. Brantner A, Kartnig TH, Quehenberger F (1994) Vergleichende phytochemische Untersuchungen an Hypericum perforatum L. und Hypericum maculatum Crantz. Scient Pharm 62: 261-276
11. Beerhues L (2006) Hyperforin. Phytochemistry 67: 2201-2207
12. Melzer M, Fuhrken D, Kolkmann R (1998) Hyperforin im Johanniskraut. Hauptwirkstoff oder nur Leitsubstanz? Dtsch Apoth Ztg 13: 4754-4760
13. Jürgenliemk G, Nahrstedt A (2002) Phenolic compounds from Hypericum perforatum. Planta Med 68: 88-91
14. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H (1984) Inhibition of monoamine oxidase by hypericin. Planta Med 50: 272-274
15. Bladt S, Wagner H (1994) Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 7(Suppl 1): 57-59
16. Cott JM (1997) In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30(Suppl 2): 108-112
17. Thiede H-M, Walper A (1994) Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 7: 54-56
18. Nielsen M, Frokjaer S, Braestrup C (1988) High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. Biochem Pharmacol 37: 3285-3287
19. Baureithel KH, Buter KB, Engesser A, Burkard W, Schaffner W (1997) Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 72: 153-157
20. Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J et al (2002) In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology (Berl) 162: 193-202
21. Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T (2001) In vitro binding studies with two hypericum perforatum extracts - hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 34(Suppl 1): 45-48
22. Raffa RB (1998) Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. Life Sci 62: L265-L270
23. Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K (1999) Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 19: 59-74
24. Simmen U, Higelin J, Berger-Büter K, Schaffner W, Lundstrom K (2001) Neurochemical studies with St. John's wort in vitro. Pharmacopsychiatry 34(Suppl 1): 137-142
25. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998) Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63: 499-510
26. Chatterjee SS, Noldner M, Koch E, Erdelmeier C (1998) Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31(Suppl 1): 7-15
27. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31(Suppl 1): 16-21
28. Buchholzer ML, Dvorak C, Chatterjee SS, Klein J (2002) Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J Pharmacol Exp Ther 301: 714-719
29. Jensen AG, Hansen SH, Nielsen EO (2001) Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 68: 1593-1605
30. Gobbi M, Valle FD, Ciapparelli C, Diomede L, Morazzoni P, Verotta L et al (1999) Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 360: 262-269
31. Neary JT, Whittemore SR, Bu Y, Mehta H, Shi YF (2001) Biochemical mechanisms of action of Hypericum LI 160 in glial and neuronal cells: inhibition of neurotransmitter uptake and stimulation of extracellular signal regulated protein kinase. Pharmacopsychiatry 34(Suppl 1): 103-107
32. Singer A, Wonnemann M, Müller WE (1999) Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 290: 1363-1368
33. Wonnemann M, Singer A, Müller WE (2000) Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188-197
34. Wonnemann M, Singer A, Siebert B, Müller WE (2001) Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry 34: 148-151
35. Fisunov A, Lozovaya N, Tsintsadze T, Chatterjee S, Noldner M, Krishtal O (2000) Hyperforin modulates gating of P-type Ca2+ current in cerebellar Purkinje neurons. Pflügers Arch 440: 427-434
36. Chatterjee S, Filippov V, Lishko P, Maximyuk O, Noldner M, Krishtal O (1999) Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci 65: 2395-2405
37. Krishtal O, Lozovaya N, Fisunov A, Tsintsadze T, Pankratov Y, Kopanitsa M et al (2001) Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 34(Suppl 1): 74-82
38. Biber A, Fischer H, Römer A, Chatterjee SS (1998) Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31(Suppl 1): 36-43
39. Butterweck V, Wall A, Liefländer-Wulf U, Winterhoff H, Nahrstedt A (1997) Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 30(Suppl 2): 117-124
40. Zanoli P, Rivasi M, Baraldi C, Baraldi M (2002) Pharmacological activity of hyperforin acetate in rats. Behav Pharmacol 13: 645-651
41. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H (2003) Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sei 73: 627-639
42. Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H (2000) Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 66: 3-6
43. Butterweck V, Korte B, Winterhoff H (2001) Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 34(Suppl 1): 2-7
44. Butterweck V, Hegger M, Winterhoff H (2004) Flavonoids of St. John's wort reduce HPA axis function in the rat. Planta Med 70: 1008-1011
45. Butterweck V, Winterhoff H, Herkenham M (2001) St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 6: 547-564
46. Gambarana C, Ghiglieri O, Tolu P, De Mentis MG, Giachetti D, Bombardelli E et al (1999) Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsychopharmacology 21: 247-257
47. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A (1998) Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 64: 291-294
48. Jürgenliemk G, Nahrstedt A (2003) Dissolution, solubility and cooperativity of phenolic compounds from Hypericum perforatum L. in aqueous systems. Pharmazie 58: 200-203
49. Nöldner M, Schötz K (2002) Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 68: 577-580
50. Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A (2003) Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 69: 189-192
51. Schulz HU, Schürer M, Bässler D, Weiser D (2005) Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multipe oral dosing of a Hypericum extract containing tablet. Arzneim-Forsch/Drug Res 55: 15-22
52. Müller SC, Uehleke B, Wöhling H, Petzsch M, Majcher-Peszynska J, Hehl EM et al. (2004) Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 75: 546-557
53. Laakmann G, Schüle C, Baghai T, Kieser M (1998) St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31(Suppl 1): 54-59
54. Hoffmann J, Kühl ED (1979) Therapie von depressiven Zuständen mit Hypericin. ZFA (Stuttgart) 55: 776-782
55. Schlich D, Braukmann F, Schenk N (1987) Behandlung depressiver Zustandsbilder mit Hypericinum. Psycho 13: 440-447
56. Schmidt U, Schenk N, Schwarz I, Vorberg G (1989) Hypericin-Applikation. Zur Therapie depressiver Verstimmungen. Psycho 15: 665-671
57. Schrader E, Meier B, Brattström A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 13: 163-169
58. Schrader E (2000) Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15: 61-68
59. Woelk H (2000) Comparison of St. John's wort and imipramine for treating depression: randomised controlled trial. Br Med J 321: 536-539
60. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V (2006) Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62: 255-233
61. Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J (2006) Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med 72: 685-690